Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs CNS deal with BioFocus

Astellas Pharma is to focus on central nervous system (CNS) disorders with the help of BioFocus

Astellas Pharma has signed a collaboration agreement with BioFocus focused on discovering novel targets in the field of central nervous system disorders.  

Under the agreement, BioFocus will utilise its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.  

Dr Chris Newton, managing director of BioFocus, said: "We are delighted to support Astellas Pharma in its research. Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology."

12th May 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....